Amarin Announces Research Evaluating Benefits Of VASCEPA/VAZKEPA To Be Presented At The American College Of Cardiology's Annual Scientific Session & Expo

Author: Benzinga Newsdesk | March 25, 2024 08:22am

-- Subgroup Analyses from REDUCE-IT® and Mechanistic Data on Icosapent Ethyl(IPE)/Eicosapentaenoic Acid (EPA) Featured at the Meeting --   

 

DUBLIN, Ireland and BRIDGEWATER, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that additional patient subgroup analyses from the landmark REDUCE-IT outcomes trial and mechanistic data on icosapent ethyl (IPE)/eicosapentaenoic acid (EPA) will be presented at the American College of Cardiology's Annual Scientific Session & Expo, April 6 – 8, 2024 in Atlanta, GA.

"The data being featured at ACC.24 continues to support and explain the clinical utility and value of VASCEPA®/VAZKEPA® (icosapent ethyl), not only in the overall REDUCE IT patient population, but in the different sub-populations analyzed so far," said Nabil Abadir, MB. CH.B., SVP, Chief Medical Officer, and Head of Global Medical Affairs at Amarin "The data highlight VASCEPA/VAZKEPA's effect on reducing MACE in patients with different baseline levels of Lipoprotein(a) [Lp(a)] including among those with clinically relevant Lp(a) elevation as well as among patients with high and low LDL-C baseline levels. These data demonstrate the molecule's impact in reducing patients' residual cardiovascular event risk across these patient sub-groups regardless of their baseline Lp(a) or LDL-C levels. Additionally, the meeting provides an opportunity to highlight further evidence regarding the potential mechanistic activity of EPA in reducing cardiovascular events in at-risk patients."

"This latest research reaffirms Amarin's commitment to advancing cardiovascular care and should help further advance the medical community's understanding of the role, the value and the potential mechanism of action of VASCEPA/VAZKEPA to reduce cardiovascular events in at-risk patients globally," concluded Abadir.

Featured Amarin-supported abstracts to be presented by international academic collaborators at ACC Scientific Sessions 2024 include:

Moderated Poster Presentations

• Icosapent Ethyl Reduces MACE in Patients with Elevated Triglycerides and High or Low Lipoprotein(a) Concentrations: A REDUCE-IT Subanalysis
  
  Michael Szarek, Deepak L. Bhatt, Elliot A. Brinton, Michael Miller, et al.
  
  –Available April 6th, 3:30-3:40 PM
  
  -Moderated Poster Theater 06
• Efficacy of Icosapent Ethyl for Reducing Cardiovascular Outcomes by Baseline Low Density Lipoprotein Cholesterol Level
  
  Rahul Aggarwal, Deepak L. Bhatt, Philippe Gabriel Steg, Michael Miller, et al.
  
  -Available Apil 6th, 12:15-12:25 PM
  
  -Moderated Poster Theater 08
• Eicosapentaenoic Acid (EPA) Inhibits Lipoprotein(a) [Lp(a)] Oxidation due to Scavenging Mechanisms in Vitro
  
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  
  -Available April 7th, 9:30-9:40 AM
  
  -Moderated Poster Theater 06

Poster Presentations

• Eicosapentaenoic Acid (EPA) and a High Intensity Statin Enhanced Expression of Proteins for Detoxification of Reactive Oxygen Species During Angiotensin II Challenge in Endothelial Cells
  
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  
  -Available April 7th, 1:15-2:00 PM
  
  -Hall B4-5
• Eicosapentaenoic Acid and Rosuvastatin Modulate Expression of Endothelial Proteins that Regulate Function and Platelet Activity During Angiotensin II Stimulation
  
  Samuel C.R. Sherratt, Peter Libby, Deepak L. Bhatt, R. Preston Mason, et al.
  
  -Available April 7th, 1:15-2:00 PM
  
  -Hall B4-5
• Effects of Icosapent Ethyl on Vascular Regenerative Cells in Individuals with Elevated Triglycerides: Insights From the IPE-Prevention Cardiolink-14 Trial
  
  Ehab Bakbak, Aishwarya Krishnaraj, Deepak L. Bhatt, Brady Park, et al.
  
  –Available April 8th, 12:45-1:30 PM
  
  - Hall B4-5

Posted In: AMRN